Today's capabilities in clinical diagnostic radiology have been made possible
by advances not only in diagnostic systems, but also by the contrast media and
radiopharmaceuticals that make it possible to see, in great detail, the body's
internal structures, organs and tissue that would nototherwise be clearly
seen. Although bones are readily apparent on radiographic images, other organs
and tissues are not. These imaging agents may be usedduring a medical imaging
procedure to highlight specific parts of the body andmake them easier to
visualize. The application and versatility of medical imaging modalities are
continuing to grow in significance as the population ages and healthcare costs
rise. Examinations that can facilitate earlier disease diagnosis and the
most appropriate treatment are in order. This bodes well for contrast media
markets.
Generally, the market for contrast agents and radiopharmaceuticals is expected
to sustain decent growth in the next fewyears, with much of that growth coming
from the MRI, ultrasound and nuclear medicine modalities. While equipment
manufacturers may have experienced a slumpin sales due to the recent
recession, there is still a need for these agents,as well as for
radiopharmaceuticals, to help image, track and diagnose disease, especially in
the elderly. Even though hospitals and clinics may have slowed their equipment
purchases because of the need to contain costs, procedures run on installed
systems still require the use of contrast agents and radiopharmaceuticals.
This comprehensive study of the world market for contrast agents builds on the
previous modality-focused reports of Kalorama's medical imaging market reports.
Coverage includes:
World and regional revenue forecasts for contrast agents and
radiopharmaceuticals by modality through 2016. (X-Ray, CT, Ultrasound, MRI,
PET, SPECT)
Market share of the major contrast agent supplers
Procedure volumes by modality and region
Estimates of the portion of procedures in each modality using contrast
enhancement
Contrast-enhancement products in development
The report also discusses technical developments and emerging application
trends such as therapeutic monitoring, whole body screening, and guided
therapeutic interventions, and how contrast agents are helping to expand
imaging's role in basic research and drug discovery/development. Specific
advances in contrast agent-enabled diagnostics for mammography, Alzheimer's,
and other indications are also reviewed.
The report concludes with profiles of top suppliers and developers including:
Acusphere Inc.
Alseres Pharmaceuticals Inc.
Amag Pharmaceuticals Inc.
Aposense Ltd.
Avid Radiopharmaceuticals Inc.
Bayer Schering Pharma
Bracco SpA
Cell Point
Covidien Ltd.
Daiichi Pharmaceutical Co. Ltd.
Dendritic NanoTechnologies Inc.
Draximage
Endocyte Inc.
Eusa Pharma
GE Healthcare
Guerbet Group
Hovione FarmaCiencia SA
Imcor Pharmaceutical Co.
Immunomedics Inc.
Insight Agents GmbH
King Pharmaceuticals Inc.
Luna nanoWorks
Macrocyclics
MDS Nordion
NanoScan Imaging
Palatin Technologies Inc.
Pharmacyclics
Point Biomedical Corp.
Starpharma Holdings Ltd.
VisEn Medical Inc.
Table of Contents
Table of Contents
CHAPTER ONE: Executive Summary
Image Enhancament Overview
X-Ray and CT
Ultrasound
MRI
Radiopharmaceuticals
World Market Summary
Volume Growth
New Diagnostics
Toxicity Issues
Generic Competition
World Market Growth Analysis
Methodology
CHAPTER TWO: Introduction
Agents for the Early Detection of Disease
Two Functions
Adding Value
Key Clinical Markets
X-Ray and CT
Ultrasound
Updated Warning on Microbubbles
Microbubble Composition
Targeted and Untargeted
MRI
Novel Agents
Nuclear Medicine
Diagnosing Functionality
Sourcing Issues Updated
PET
New Applications
SPECT
Gamma Cameras
Risks
Ionic and Non-Ionic Contrast
Issues
Utilization Rate
Technical Challenges
Tracking Contrast Media
Contrast Modality Combinations
Emerging Applications
Atherosclerosis
Nanotechnology
CHAPTER THREE: Market Developments
Market Developments
FDA Approves Amyvid
Bayer HealthCare Business Integration
Bayer Receives Gadavist Approval
Agfa's Generic Push
Agfa's Generic Push
Improving Magnetic Resonance Visualization
Nanoparticle Contrast
Tracking Stem Cells
CHAPTER FOUR: Markets
Market Drivers
Withstanding the Recession
Combination Imaging and Disease Management
Opportunities from Increasing Specificity
Aging Population
Utilization
Procedures
Outlook for Contrast Media
Market Forecast
X-Ray and CT
Ultrasound
MRI
Outlook for Molecular Imaging Agents
Market Forecast
CHAPTER FIVE: Corporate Profiles
Acusphere Inc.
Alseres Pharmaceuticals, Inc.
Amag Pharmaceuticals Inc.
Aposense Ltd
ART Advanced Research Technologies Inc.
Avid Radiopharmaceuticals Inc.
Bayer HealthCare
Bracco SpA
Cardinal Health
Cell>Point
Covidien plc
Daiichi Pharmaceutucal Co., Ltd.
Draximage
Endocyte Inc.
Eusa Pharma
FluoroPharma Medical Inc.
GE Healthcare
Guerbet Group
Hovione Farmaciencia SA
Immunomedics Inc.
Insight Agents
Kereos Inc.
King Pharmaceuticals
Lantheus Medical Imaging
Luna Nanoworks
Macrocyclics
MDS Nordion
Molecular Insight Pharmaceuticals, Inc.
Nanoscan Imaginf LLC
Palatin Technologies Inc.
Pharmacyclics
Spago Imaging AB
Targeson Inc.
Taejoon Pharmaceutical Co., Ltd.
VisEn Medical
Zim Laboratories India Ltd.
List of Exhibits
CHAPTER ONE: Executive Summary
Exhibit 1: World Market for X-Ray Medical Contrast Media, 2011-2015
Exhibit 2: World Market for CT Medical Contrast Media, 2011-2015
Exhibit 3: World Market for Ultrasound Medical Contrast Media, 2011-2015
Exhibit 4: World Market for MRI Medical Contrast Media, 2011-2015
Exhibit 5: World Market for PET Radiopharmaceuticals, 2011-2015
Exhibit 6: World Market for SPECT Radiopharmaceuticals, 2011-2015
CHAPTER TWO: Introduction
Exhibit 7: Key Medical Contrast Agents by Type
Exhibit 8: Advantages of Non-Ionic Contrast Media Markets
Exhibit 9: Patent Status of Selected Medical Imaging Agents
CHAPTER FOUR: MARKETS
Exhibit 10: World Market for Medical Contrast Media and
Radiopharmaceuticals, 2011-2015
Exhibit 11: World Market Share for Medical Contrast Media and
Radiopharmaceuticals, 2011
Exhibit 12: World Market for Medical Contrast Media and
Radiopharmaceuticals, 2015
Exhibit 13: Key Players' Percentage Share - Worldwide Medical Contrast
Media Market, 2012
Exhibit 14: World Market Geographic Segmentation for Medical X-Ray
Procedures, 2012
Exhibit 15: World Market Geographic Segmentation for Medical X-Ray
Procedures, 2012
Exhibit 16: Worldwide Medical MRI Procedures, 2012
Exhibit 17: World Market Geographic Segmentation for Medical MRI
Procedures, 2012
Exhibit 18: Worldwide Medical CT Procedures, 2012
Exhibit 19: World Market Geographic Segmentation for Medical CT
Procedures, 2012
Exhibit 20: Worldwide Medical Ultrasound Procedures, 2012
Exhibit 21: World Market Geographic Segmentation for Medical Ultrasound
Procedures, 2012
Exhibit 22: Worldwide Medical PET Procedures, 2012
Exhibit 23: World Market Geographic Segmentation for Medical PET
Procedures, 2012
Exhibit 24: Worldwide Medical SPECT Procedures, 2012
Exhibit 25: World Market Geographic Segmentation for Medical SPECT
Procedures, 2012
Exhibit 26: Status of Selected Medical Imaging Agents
Exhibit 27: World Markets for X-Ray Contrast Media, 2011-2015
Exhibit 28: World Market for Medical X-Ray Contrast Media by Geographic
Segment, 2011-2015
Exhibit 29: World Market for Medical X-Ray Contrast Media by Geographic
Segment, 2012
Exhibit 30: World Market for CT Contrast Media, 2011-2015
Exhibit 31: World Market for Medical CT Contrast Media by Geographic
Segment, 2011-2015
Exhibit 32: World Market for Medical CT Contrast Media by Geographic
Segment, 2012
Exhibit 33: World Market for Ultrasound Contrast Media, 2011-2015
Exhibit 34: World Market for Medical Ultrasound Contrast Media by
Geographic Segment, 2011-2015
Exhibit 35: World Market for Medical Ultrasound Contrast Media by
Geographic Segment, 2012
Exhibit 36: World Market for MRI Contrast Media by Geographic Segment,
2011-2015
Exhibit 37: World Market for Medical MRI Contrast Media by Geographic
Segment, 2011-2015
Exhibit 38: World Market for Medical MRI Contrast Media by Geographic
Segment, 2012
Exhibit 39: Selected Molecular Imaging Products
Exhibit 40: World Market for Medical PET Radiopharmaceuticals, 2011-2015
Exhibit 41: World Market for Medical PET Radiopharmaceuticals by
Geographic Segment, 2011-2015
Exhibit 42: World Market for Medical PET Radiopharmaceuticals by
Geographic Segment, 2012
Exhibit 43: World Market for Medical SPECT Radiopharmaceuticals, 2011-2015
Exhibit 44: World Market for Medical SPECT Radiopharmaceuticals by
Geographic Segment, 2011-2015
Exhibit 45: World Market for Medical SPECT Radiopharmaceuticals by
Geographic Segment, 2012
Medical Imaging Markets: Contrast Agents published by Kalorama Information in July 9, 2012. This report consists of 154 Pages and the price starts from US $ 3995.
The contents of this page may be different from the latest version. Please contact us for details.
